The European Commission recently awarded VALFIX Medical with the Seal of Excellence, a high-quality certificate for first-class innovative ideas worthy of investment. VALFIX Medical is developing the first complete trans-catheter solution that combines repair and replacement treatments for Heart-Failure patients suffering from severe Mitral Regurgitation (MR); offering a viable alternative to open-heart surgery.
VALFIX submitted a proposal with the European Commission’s Horizon 2020 SME funding program. After an extensive review by an international panel of independent experts, VALFIX received the Seal of Excellence meaning VALFIX surpassed the quality threshold and the European Commission recommends VALFIX proposal for funding.
“For us at VALFIX Medical it is an honor to have our efforts recognized by the European Commission. This recognition is incredibly fulfilling as it comes from an international panel of independent experts in a highly competitive evaluation process,” commented VALFIX Medical’s CEO and Founder, Eli Bar. “We are proud that our project scored so highly against nearly 2000 applicants and this award reinforces our commitment to integrating innovation and quality as a value and approach in all of our work”.
Receiving the Seal of Excellence means the European Commission recognizes VALFIX Medical as a highly innovative company with clear potential to compete internationally in a high-growth market.